Menu

Blog Posts

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

(BUSINESS WIRE) -- KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.

JB brings more than two …

Read more

ExaGrid Appoints Sam Elbeck as VP of Americas Sales and Channel Partners

MARLBOROUGH, Mass. - Thursday, 04. April 2024 AETOSWire

New VP will drive sales and grow channel partnerships

(BUSINESS WIRE) -- ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the appointment of Sam Elbeck as the new VP of Americas Sales and Channel Partners.

Read more

Indri Becomes the Fastest Growing Single Malt Brand in the World: Sells Over One Hundred Thousand Cases in Its Second Year

NEW DELHI - Saturday, 13. April 2024 AETOSWire Print 


Captures 30% Market Share in India With A Growth Of 599% Surpassing Global Giants

(BUSINESS WIRE) -- Indri, India’s 1st and most awarded triple cask single malt, by Piccadily Distilleries, has further solidified India’s growth story with…

Read more

Central Pattana Sets the Stage for 'Thailand's Songkran Festival 2024

Central Pattana plc, Thailand’s leading real estate developer for sustainability and operator of Central shopping centers nationwide, including iconic destinations such as Central World Bangkok, Central Village Bangkok Luxury Outlet, Central Pattaya, Central Phuket, and Central Samui, is launching t…

Read more

Hong Kong Gifts & PrintPack Fairs Open in April

(BUSINESS WIRE)--Hong Kong Trade Development Council:

HKTDC Hong Kong Gifts & Premium Fair

Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 Ap…

Read more

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with…

Read more

ExaGrid Named a Finalist for the Storage Awards 2024

MARLBOROUGH, Mass. - Thursday, 11. April 2024

ExaGrid Product Line, Partner Program, and Team Nominated in 12 Categories at “The Storries XXI”

(BUSINESS WIRE)--ExaGrid®, the industry’s only Tiered Backup Storage solution with Retention Time-Lock and the only non-network-facing tiered air g…

Read more

Giesecke+Devrient Sets New Highs and Generates Revenues of Three Billion Euros for the First Time

(BUSINESS WIRE)--Giesecke+Devrient (G+D) achieved the strongest growth in its history in fiscal year 2023, setting new records for sales, sales growth, and earnings. The G+D Group is entering a new phase in the company's development, and is helping to shape the digital transformation of society as a…

Read more

NetApp Partners with Google Cloud to Maximize Flexibility for Cloud Data Storage

New Google Cloud NetApp Volumes capabilities and integrations make the cloud more secure and simple for key initiatives such as generative AI

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced an expansion of its partnership with Google Cloud to …

Read more

Corebridge Financial Completes Sale of UK Life Insurance Business to Aviva plc

HOUSTON -
(BUSINESS WIRE)--Corebridge Financial, Inc. (NYSE: CRBG) today announced that it has completed the previously announced sale of its UK life insurance business (operating as AIG Life Limited) to Aviva plc.

The transaction allows Corebridge to focus on Life & Retirement products and solu…

Read more

View older posts »

Blog Posts

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

(BUSINESS WIRE) -- KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.

JB brings more than two …

Read more

ExaGrid Appoints Sam Elbeck as VP of Americas Sales and Channel Partners

MARLBOROUGH, Mass. - Thursday, 04. April 2024 AETOSWire

New VP will drive sales and grow channel partnerships

(BUSINESS WIRE) -- ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the appointment of Sam Elbeck as the new VP of Americas Sales and Channel Partners.

Read more

Indri Becomes the Fastest Growing Single Malt Brand in the World: Sells Over One Hundred Thousand Cases in Its Second Year

NEW DELHI - Saturday, 13. April 2024 AETOSWire Print 


Captures 30% Market Share in India With A Growth Of 599% Surpassing Global Giants

(BUSINESS WIRE) -- Indri, India’s 1st and most awarded triple cask single malt, by Piccadily Distilleries, has further solidified India’s growth story with…

Read more

Central Pattana Sets the Stage for 'Thailand's Songkran Festival 2024

Central Pattana plc, Thailand’s leading real estate developer for sustainability and operator of Central shopping centers nationwide, including iconic destinations such as Central World Bangkok, Central Village Bangkok Luxury Outlet, Central Pattaya, Central Phuket, and Central Samui, is launching t…

Read more

Hong Kong Gifts & PrintPack Fairs Open in April

(BUSINESS WIRE)--Hong Kong Trade Development Council:

HKTDC Hong Kong Gifts & Premium Fair

Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 Ap…

Read more

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with…

Read more

ExaGrid Named a Finalist for the Storage Awards 2024

MARLBOROUGH, Mass. - Thursday, 11. April 2024

ExaGrid Product Line, Partner Program, and Team Nominated in 12 Categories at “The Storries XXI”

(BUSINESS WIRE)--ExaGrid®, the industry’s only Tiered Backup Storage solution with Retention Time-Lock and the only non-network-facing tiered air g…

Read more

Giesecke+Devrient Sets New Highs and Generates Revenues of Three Billion Euros for the First Time

(BUSINESS WIRE)--Giesecke+Devrient (G+D) achieved the strongest growth in its history in fiscal year 2023, setting new records for sales, sales growth, and earnings. The G+D Group is entering a new phase in the company's development, and is helping to shape the digital transformation of society as a…

Read more

NetApp Partners with Google Cloud to Maximize Flexibility for Cloud Data Storage

New Google Cloud NetApp Volumes capabilities and integrations make the cloud more secure and simple for key initiatives such as generative AI

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced an expansion of its partnership with Google Cloud to …

Read more

Corebridge Financial Completes Sale of UK Life Insurance Business to Aviva plc

HOUSTON -
(BUSINESS WIRE)--Corebridge Financial, Inc. (NYSE: CRBG) today announced that it has completed the previously announced sale of its UK life insurance business (operating as AIG Life Limited) to Aviva plc.

The transaction allows Corebridge to focus on Life & Retirement products and solu…

Read more

View older posts »

Blog Component

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

(BUSINESS WIRE) -- KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.

JB brings more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and the latest advancements in cell and gene therapies. With a proven track record of implementing winning sales strategies and cultivating high-performing teams, JB will lead KBI’s global business development initiatives, driving the company towards continued growth and sustained success. This pivotal role is focused on building and maintaining long-lasting partnerships with KBI’s current and future customers around the globe. JB’s commitment to fostering relationships with external partners and internal team members alike is a value that aligns well with KBI’s collaborative culture.

“Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” remarked J.D. Mowery, President & CEO of KBI Biopharma. “JB’s appointment underscores this dedication, perfectly aligning with our team’s mission to deliver innovative, top-tier solutions tailored to our customers' evolving needs. His servant leadership philosophy will further fortify our team, propelling KBI to new heights.”

“KBI Biopharma is an innovator in the testing, development, manufacturing, and commercialization of life-changing therapies,” said JB Agnus, Chief Business Officer of KBI Biopharma. “Strong partnerships are at the core of KBI’s success. I am excited to join the passionate team at KBI, who are committed to ensuring transformative treatments reach those in need by nurturing meaningful customer relationships.”

Before joining KBI, JB held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem. He holds a Master of Science in Chemical Engineering from Centrale Marseille.

About KBI Biopharma, Inc.

KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.

Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415842099/en/


Permalink
https://www.aetoswire.com/en/news/1504202438697
Contacts
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com

KBI Biopharma, Inc. Media Inquiries
Kelly Biele
CG Life
kbiele@cglife.com

ExaGrid Appoints Sam Elbeck as VP of Americas Sales and Channel Partners

MARLBOROUGH, Mass. - Thursday, 04. April 2024 AETOSWire

New VP will drive sales and grow channel partnerships

(BUSINESS WIRE) -- ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the appointment of Sam Elbeck as the new VP of Americas Sales and Channel Partners.

“I am looking forward to working with the ExaGrid sales teams throughout the Americas, and help ExaGrid accelerate its growth within the $6 billion backup storage market,” said Sam Elbeck. He will work with the local ExaGrid teams across the U.S., Canada, and Latin America, alongside each Area Vice President, to strengthen channel partnerships and build successful programs with leading reseller partners in each region.

Sam Elbeck recently joined ExaGrid after his position as VP of Sales and Partnerships Americas for Arcserve, and prior to that he was Senior Global Director of Sales for Digital Compliance and SaaS Backup at Veritas. Sam was also VP of Sales and Business Development for Globanet, and held sales and technical leadership roles at both Symantec and IBM.

“ExaGrid is continuing to expand, with sales teams in more than 30 countries, as well as 4,200 active customer installations in more than 80 countries,” said Bill Andrews, President and CEO of ExaGrid. “We are pleased to welcome Sam Elbeck who will lead the sales teams in the Americas, and work with them to grow our partnerships in the channel and bring our Tiered Backup Storage solution to more organizations.”

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404887465/en/


Permalink
https://aetoswire.com/en/news/0404202438579
Contacts
Media:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com

 

Indri Becomes the Fastest Growing Single Malt Brand in the World: Sells Over One Hundred Thousand Cases in Its Second Year

NEW DELHI - Saturday, 13. April 2024 AETOSWire Print 


Captures 30% Market Share in India With A Growth Of 599% Surpassing Global Giants

(BUSINESS WIRE) -- Indri, India’s 1st and most awarded triple cask single malt, by Piccadily Distilleries, has further solidified India’s growth story with Indri-Trini becoming the ‘fastest growing single malt in the world ever’. No other single malt brand from Scotland, Japan, Taiwan or anywhere else in the world has ever been able to cross the hundred thousand (100 K) cases mark within two years of its launch. With this feat, Indri-Trini has shattered all expectations and broken into the elite club of top selling single malts in the world.

With an unprecedented growth rate of 599% compared to last year, Indri is not just breaking records; it's reinventing the game. Indri has trailblazed its way to capture 30% market share in India. Piccadily Distilleries, with its ambitious expansion plans, envisions becoming one of the top 5 selling single malt brand in the world.

Since its debut in November 2021, Indri’s brand journey from inception to this extraordinary milestone has witnessed over 25 global coveted accolades including 'Best Indian Single Malt' at prestigious competitions like the World Whisky Awards and the International Whisky Competition. With notable titles such as 'Asian Whisky of the Year' and a 'Gold Medal' at the New York World Wine & Spirits Competition, Indri has made India immensely proud on a global scale. Its crowning achievement came when its Indri Diwali Collector’s Edition was declared 'Best Whisky In The World' at the Whiskies of the World Awards, surpassing Scotch and American rivals. This success has not only elevated the brand but also bolstered the reputation of Indian whiskies internationally, sparking a surge in demand for premium Indian single malts.

The rise of Indri is indicative of a seismic shift in consumer behaviour and preferences with premium sprits leading the way. As per industry reports, Indian single malts have staged a coup, outpacing their Scottish counterparts with a staggering 144% surge in 2021-22 and the momentum is only building. Early estimates by the Confederation of Indian Alcoholic Beverage Companies (CIABC) indicate that Indian single malts commanded a jaw-dropping 53% of total sales in 2023, leaving imported brands trailing behind.

“In a market once dominated by imported labels, Indri stands tall as a beacon of Indian excellence. It's not just a brand; it's a symbol of national pride, elevating the status of Indian spirits to unparalleled heights. Indri isn't just leading the charge; it's leading a revolution,” said CEO, Piccadily Distilleries, Praveen Malviya.

As Indri continues to redefine the standards of Indian single malts, Piccadily Distilleries remains dedicated to pushing boundaries, exploring new horizons, and delivering exceptional experiences to whisky enthusiasts worldwide.

Stock Ticker: (PICCADIL | 530305 | INE546C01010)

https://www.bseindia.com/stock-share-price/piccadily-agro-industries-ltd/piccadily-agro-inds/530305/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240412989230/en/


Permalink
https://www.aetoswire.com/en/news/1304202438690
Contacts
For more information, contact:
Shreya Bhattacharya – shreyab@avianwe.com | +91-9582891650
Rutvi Mehta – rutvim@avianwe.com | +91-86194 30473
Abhishek Haryson – a.haryson@piccadily.com | +91 9891356547

Central Pattana Sets the Stage for 'Thailand's Songkran Festival 2024

Central Pattana plc, Thailand’s leading real estate developer for sustainability and operator of Central shopping centers nationwide, including iconic destinations such as Central World Bangkok, Central Village Bangkok Luxury Outlet, Central Pattaya, Central Phuket, and Central Samui, is launching the biggest global entertainment campaign: 'THAILAND'S SONGKRAN FESTIVAL 2024 - The Great Songkran Entertainment'. The festival will run from April 2nd to April 21st, 2024, at Central shopping centers nationwide. Songkran, known as the Thai New Year, is one of Thailand's most iconic festivals, celebrated nationwide in April, marked by water fights, temple visits, and family reunions.

Central Pattana aims for 'Thailand's Songkran' to be listed among the Top 10 global festivals. The campaign features 1,000 events, including six major highlights combining culture with entertainment. The highlight includes an international surprise: Miss Universe 2023, Sheynnis Palacios, will be sent directly from the Miss Universe stage to become Miss Songkran in Thailand and serve as a Global Cultural Ambassador to promote 'The Best of Thainess' worldwide.

Dr. Nattakit Tangpoonsinthana, Chief Marketing Officer for Central Pattana plc, expressed, “This year, Central Pattana has a key mission to ‘Bring Thainess to The World’. We aim to serve as a platform to promote Thailand’s Songkran worldwide and become one of the top ten global festivals, following government policy. Songkran goes beyond a mere water-splashing festival; it integrates the beauty of local culture and traditions for each region. Central shopping centers nationwide are ready to serve as a global 'culturetainment' landmark, welcoming both Thai and foreign tourists from around the world, ensuring that Thailand is the global destination of choice for every festival.

“In addition, we have established the 'Tourist Hub Destination' strategy in our 15 branches located in popular tourist cities nationwide, attracting tourists worldwide by curating world-class shopping experiences. We are collaborating with travel platforms such as Klook, Trip.com, KK Day, Go City, and top airlines like Thai Airways, AirAsia, and more, as well as launching special promotions with international banks such as JCB, UnionPay, and UOB. We look forward to welcoming everyone to experience the fun and exciting activities throughout the Songkran festival at Central shopping centers nationwide.”

Discover Six Major Highlights at Central During the Songkran Festival:

Music Festival & Water Fight Entertainment: Central offers 30 landmarks for the 'World's Best Water Fight Entertainment', extending the fun throughout Thailand for over half a month at Central shopping centers nationwide. Highlighting centralwOrld as a world-class Songkran landmark in the heart of the city with the 'centralwOrld Songkran Fest 2024', featuring the Thai Rhythm Songkran Festival 2024 and the Wan Lai Songkran at the FWD Music Live Fest.

Thai Entertainment: Enjoy special showcases of world heritage Thai culture, including performances from the Ministry of Culture such as Thai boxing, Khon Yok Rob, Thai Traditional Southern Dance, and contemporary Thai Dance.

Happy Entertainment: Participate in activities to enhance good fortune for the Thai New Year by paying homage and receiving blessings from respected temples.

Delicious Entertainment: Celebrate Songkran and Family Day by shopping and tasting delicious local Thai food at the Thai Market in a cool and comfortable atmosphere.

Thai Costume Entertainment: Encouraging visitors to wear Thai traditional/local costumes throughout April, with Thai Costume Rental available at shopping centers.

Shopping Entertainment: The campaign is packed with promotions, including exclusive offers for foreign customers. Visitors can register for The 1 Tourist membership to receive free Premium Gifts & Welcome Packages valued up to 10,000 Thai baht, along with other special privileges.

*Terms and conditions apply.


Permalink
https://aetoswire.com/en/news/cp10202404eng
Contacts
Rebecca Travasso

rebecca@mediarepublic.biz

Hong Kong Gifts & PrintPack Fairs Open in April

(BUSINESS WIRE)--Hong Kong Trade Development Council:

HKTDC Hong Kong Gifts & Premium Fair

Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 April, with the online matching services “Click2Match” available from 20 April to 7 May. It offers an ideal platform for exhibitors to showcase their latest products, and foster networking and collaboration among industry professionals.

The Hall of Fine Designs will return as a convergence of reputed global brands, including Red A (Hong Kong), Tiny Memory (Hong Kong), YASHICA (Japan) and more. The pavilion formed by Hong Kong Exporters' Association will showcase the design skills and branding excellence of local product designers. Winning works from the Hong Kong Smart Design Awards will also be displayed to highlight the creativity and flair of Hong Kong brands to global industry players.

The anticipated Cultural & Creative Corner will captivate visitors with its vibrant showcase of designer brands and products with unique styles. Catering to the latest trends, the brand-new Outdoor & Sporting Goods zone will showcase a series of products including camping gear, dance shoes, and sporting goods.

To keep visitors abreast of the latest market information and encourage networking, there will be seminars hosted by industry players and associations to share insights on areas crucial to the sector’s development such as consumer market trends, sustainability and silver economy.

Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong

Jointly organised by the Hong Kong Trade Development Council and CIEC Exhibition Company (HK) Limited, the two printpack Fairs will be held from 27-30 April at AsiaWorld-Expo, with the online matching services “Click2Match” available from 20 April to 7 May.

The Printing & Packaging Fair is a premier marketplace to source printing and packaging equipment, products and services. As global demand for luxury packaging grows, the acclaimed World of DeLuxe PrintPack Zone at the Fair will spin off and launch as DeLuxe PrintPack Hong Kong this year. Together, the two Fairs will host around 500 exhibitors, offering a comprehensive showcase of industry-leading solutions.

Highlighted Zones:

Green Printing & Packaging: bio-degradable materials, upcycled products and innovative green solutions
Food & Beverage Packaging: functional solutions designed for fresh, chilled, and processed food
E-commerce Packaging: creative solutions for enterprises to capture e-tailing opportunities
The debut DeLuxe PrintPack will present an array of printing and packaging solutions tailored for luxury goods including jewellery, watches, cosmetics, gourmet food, and wine.

Forums and networking activities will be held share industry trends, sustainable designs and the impact of deluxe packaging on brand identity. Award-winning entries from the Hong Kong Print Awards, the Hong Kong Digital Printing Award and the GAAHK x PolyU Design - Packaging Design will be presented to showcase innovations in printpack design and production.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408808037/en/


Permalink
https://aetoswire.com/en/news/9042024386199
Contacts
HKTDC's Exhibitions Department:
Joanne Ma/Timothy Hsu
(852) 2240 4602 / 2240 4308
joanne.ts.ma@hktdc.org / timothy.tf.hsu@hktdc.org

 

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14. The agreement covers markets such as the United States, the European Union, and Canada. An exception to the agreement is China.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408963530/en/

The randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study (NCT05352516) aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia®) in postmenopausal women with osteoporosis at high risk for fracture. Eligible patients were randomised at a 1:1 ratio to receive subcutaneous injection of 60 mg of HLX14 or reference denosumab (Prolia®) every six months. The primary efficacy endpoint of this study was the percentage change in bone mineral density (BMD) at the lumbar spine from baseline to Week 52 (D365) assessed by central imaging. The primary pharmacodynamic endpoint was the area under the effect–time curve for percentage change of serum type I collagen C-telopeptide (s-CTX) from baseline to Week 26 (D183) (AUEC0–26W). The primary endpoints of this study were met.

Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 2 have been approved for marketing in overseas markets, 19 indications are approved worldwide, and 7 marketing applications have been accepted for review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Facility and Songjiang First Plant, both certificated by China and the EU GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®), the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.

To learn more about Henlius, visit www.henlius.com/en/ or connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.

Cautionary Note Regarding Forward-Looking Statements

Some statements and disclosures in this press release are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about expectations regarding Organon’s license and supply agreement with Henlius. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning. These forward-looking statements are based on Organon’s current plans and expectations and are subject to a number of risks and uncertainties that could cause Organon’s plans and expectations, including actual results, to differ materially from the forward-looking statements.

Risks and uncertainties that may affect Organon’s future results include, but are not limited to, our inability to successfully commercialize products in our biosimilars portfolio, the performance, operations and regulatory compliance of Henlius and its suppliers, efficacy, safety, or other quality concerns with respect to marketed products, including market actions such as recalls, withdrawals, or declining sales; political and social pressures or regulatory developments, that adversely impact demand for, availability of, or patient access to Organon’s products; general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of Organon’s patents and other protections for innovative products; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408963530/en/


Permalink
https://aetoswire.com/en/news/53922420en
Contacts
 
Organon Media Contacts:

Karissa Peer
(614) 314-8094

Hannah Silver
(917) 509-8864

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Alex Arzeno
(203) 550-3972

Henlius Media Contacts

Bella Zhou
wenting_zhou@henlius.com

Janice Han
jiayi_han@henlius.com

 

ExaGrid Named a Finalist for the Storage Awards 2024

MARLBOROUGH, Mass. - Thursday, 11. April 2024

ExaGrid Product Line, Partner Program, and Team Nominated in 12 Categories at “The Storries XXI”

(BUSINESS WIRE)--ExaGrid®, the industry’s only Tiered Backup Storage solution with Retention Time-Lock and the only non-network-facing tiered air gap with delayed deletes and immutability for ransomware recovery, today announced that it has been nominated in 12 categories for the 21st annual Storage Awards.

ExaGrid has become a finalist in the following categories:

Immutable Storage Company of the Year
Storage Industry Champion – Commercial: ExaGrid – Belinda Fairon
Storage Industry Champion – Technical: ExaGrid – Graham Woods
Storage Industry Champion – Marketing: ExaGrid – Mary Domenichelli
Cyber Resilient Storage Company of the Year
Data Protection Company of the Year
Enterprise Backup Hardware Vendor of the Year
Storage Optimisation Company of the Year
Capacity Storage Vendor of the Year
Channel Partner Program of the Year
Storage Product of the Year
Storage Company of the Year
 

Voting to determine the winner in each category is underway now and closes on May 23, 2024. Winners of this year’s awards will be announced at “The Storries XXI” awards ceremony held in London on June 6, 2024.

“We are grateful to the Storage Awards for its recognition of our Tiered Backup Storage solution, our innovative Reseller Partner Program, our industry-leading customer support, and of the individual members of the ExaGrid Team,” said Bill Andrews, President and CEO of ExaGrid. “We are honored to be nominated in so many categories, and we are looking forward to the ‘The Storries XXI’ awards ceremony in June.”

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411805562/en/


Permalink
https://www.aetoswire.com/en/news/ex-20240411805562r1
Contacts
 
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com

Giesecke+Devrient Sets New Highs and Generates Revenues of Three Billion Euros for the First Time

(BUSINESS WIRE)--Giesecke+Devrient (G+D) achieved the strongest growth in its history in fiscal year 2023, setting new records for sales, sales growth, and earnings. The G+D Group is entering a new phase in the company's development, and is helping to shape the digital transformation of society as a leading global SecurityTech company.

2023 was a year of growth for G+D with the company generating revenue of three billion euros. G+D surpassed its previous record from 2022 by 18%. Earnings before interest, taxes, depreciation and amortization (EBITDA) rose by 17% to 347 million euros, the highest figure in the company's history. Annual net income increased by 14% to 92 million euros.

G+D's high volume of incoming orders, standing at 3.2 billion euros, points to continued future success. At the same time G+D is consistently investing in the expansion of its portfolio and the Group’s development. In 2023, G+D invested an unprecedented 490 million euros – an increase of 44% compared to 2022.

The Group's portfolio is segmented into Digital Security, Financial Platforms and Currency Technology. Integrated security technology, with which G+D strengthens the trust of citizens and consumers in the digital age, is the common denominator across all these segments. In Digital Security, G+D protects and manages confidential systems, networks, data and identities. In Financial Platforms, G+D offers solutions for payments and banking. As a global market leader in Currency Technology, G+D offers secure solutions for public currencies in physical and digital ecosystems including solutions for central bank digital currencies.

"We have achieved the most successful fiscal year in the company's history and are now entering a new phase in our development," said Ralf Wintergerst, Group CEO of G+D. "This gives us a strong basis for further strategic development as a SecurityTech company and for making the lives of billions of people more secure with our products and solutions."

Further information here.

About Giesecke+Devrient

G+D is a global SecurityTech company headquartered in Munich, Germany. The company shapes trust in the digital age, with built-in security technology in three segments: Digital Security, Financial Platforms and Currency Technology.

G+D was founded in 1852 and today has a global workforce of more than 14,000 employees in 40 countries. In 2023, the company generated a turnover of 3 billion euros. Website: www.gi-de.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411824313/en/


Permalink
https://aetoswire.com/en/news/20240411824313r1
Contacts
 
PR-COM
Nicole Oehl
nicole.oehl@pr-com.de

NetApp Partners with Google Cloud to Maximize Flexibility for Cloud Data Storage

New Google Cloud NetApp Volumes capabilities and integrations make the cloud more secure and simple for key initiatives such as generative AI

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced an expansion of its partnership with Google Cloud to make it easier for organizations to leverage their data for generative AI (GenAI) and other hybrid cloud workloads. NetApp and Google Cloud are announcing the Flex service level for Google Cloud NetApp Volumes which supports storage volumes of nearly any size. NetApp is also releasing a preview of its GenAI toolkit reference architecture for retrieval-augmented generation (RAG) operations using Google Cloud Vertex AI platform.

More Flexible Data Storage Options for Google Cloud NetApp Volumes

Google Cloud and NetApp are announcing a new service level for NetApp Volumes called Flex that gives customers more granular control to adapt their storage and performance to match the exact needs of their cloud workloads.

“Increasing demand for data-intensive applications and insights has reinforced the need for a new approach to unified data storage that gives organizations the agility to move and store data wherever it is needed at any point in time,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “By extending our collaboration with Google Cloud, we’re delivering a flexible form factor that can be run on existing infrastructure across Google Cloud system without any tradeoffs to enterprise data management capabilities.”

With the addition of Flex, NetApp Volumes customers can choose from four service levels to leverage a fully managed file service built on NetApp ONTAPTM and operated by Google Cloud, including:

Standard: highly available, general-purpose storage with advanced data management capabilities and 16MiB/sec per TiB of performance, which is recommended to support workloads such as file shares, virtual machines (VMs), and DevTest environments.
Premium: highly available, high-performance storage with advanced data management capabilities and 64MiB/sec per TiB of performance, which is recommended for file shares, VMs, and databases.
Extreme: highly available, low-latency, high-throughput storage with advanced data management capabilities and 128MiB/sec per TiB of performance, which is recommended for Online Transaction Processing (OLTP) high-performance databases and low-latency applications.
Flex: highly available storage volumes with scalability from one GiB to 100TiB and up to one GiB/s of performance depending on the size of the underlying storage pool. This adaptable service level can support a wide variety of use cases, including AI.
“Google Cloud NetApp Volumes remains a critical component of every enterprise’s digital transformation strategy,” said Sameet Agarwal, GM/VP, Google Cloud Storage at Google Cloud. “Utilizing Google Cloud technologies, NetApp Volumes will power new capabilities that can improve how businesses operate and create real-world value for their organizations.”

The Flex service level will be generally available by Q2 2024 across 15 Google Cloud regions, expanding to the other Google Cloud regions by the end of 2024.

Unlocking Enterprise Data for Generative AI in Google Cloud

NetApp is also releasing a preview of its GenAI toolkit with support for NetApp Volumes. This offering, along with the accompanying reference architecture, speeds the implementation of RAG operations while enabling secure, consistent, and automated workflows that securely connect data stored in NetApp Volumes with Google Cloud Vertex AI platform. The result is a greater ability to generate unique, high-quality, and ultra-relevant insights and automations.

“As the intelligent data infrastructure company, we have unmatched capabilities to support data classification, tagging, mobility, and cloning for data wherever it lives so our customers can run efficient and secure AI data pipelines,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “Building on our partnership with Google Cloud to streamline RAG enables customers to tap into market-leading AI services and models to generate a unique competitive advantage.”

The NetApp GenAI toolkit helps optimize RAG processes with unique capabilities, including:

Common data footprint everywhere: NetApp ONTAP allows customers to easily include data from any environment to power their RAG efforts with common operational processes while reducing risk, cost, and time to results.
Automated classification and tagging: NetApp’s BlueXP classification service automatically tags data to support streamlined data cleansing for both the ingest and inferencing phases of the data pipeline, ensuring that the right data is used for queries and that sensitive data is not exposed to the model out of policy.
Fast, scalable snapshots: ONTAP Snapshot delivers near-instant creation of space-efficient, in-place copies of vector stores and databases, allowing immediate roll back to a previous version if data is corrupted or forward if point-in-time analysis is needed.
Real-time cloning at scale: ONTAP FlexClone technology can create instant clones of vector index stores to safely make uniquely relevant data instantly available for different queries for different users, without impacting the core production data.
“GenAI is a tidal wave of opportunity for the companies that can effectively apply their data to their industry,” said Miles Ward, CTO at SADA, An Insight Company. “At SADA we are fired up about pairing our extensive expertise with NetApp and Vertex AI to help customers accelerate their AI journeys. Why generate uninformed chats when you could generate unique, specific, relevant insights?”

The GenAI toolkit will be available as a public preview within the second half of 2024.

To learn more about the Flex service level for NetApp Volumes or the GenAI toolkit reference architecture for Vertex AI, visit the NetApp booth #1231 at the Google Cloud Next 2024 conference running from April 9-11 at Mandalay Bay in Las Vegas.

Additional Resources

All Your Datasets are Welcome on Google Cloud NetApp Volumes. Did We Say No Trade-Offs?
Introducing Google Cloud NetApp Volumes Flex Service Level
Google Cloud NetApp Volumes
About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410415954/en/


Permalink
https://aetoswire.com/en/news/53927502
Contacts
 
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com

Corebridge Financial Completes Sale of UK Life Insurance Business to Aviva plc

HOUSTON -
(BUSINESS WIRE)--Corebridge Financial, Inc. (NYSE: CRBG) today announced that it has completed the previously announced sale of its UK life insurance business (operating as AIG Life Limited) to Aviva plc.

The transaction allows Corebridge to focus on Life & Retirement products and solutions in the United States.

J.P. Morgan Securities LLC acted as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal counsel to Corebridge.

About Corebridge Financial

Corebridge Financial, Inc. makes it possible for more people to take action in their financial lives. With more than $380 billion in assets under management and administration as of December 31, 2023, Corebridge Financial is one of the largest providers of retirement solutions and insurance products in the United States. We proudly partner with financial professionals and institutions to help individuals plan, save for and achieve secure financial futures. For more information, visit corebridgefinancial.com and follow us on LinkedIn and YouTube. These references with additional information about Corebridge have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

About AIG

American International Group, Inc. (NYSE: AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in approximately 190 countries and jurisdictions protect their assets and manage risks through AIG operations and network partners. For additional information, visit www.aig.com. This website with additional information about AIG has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

AIG is the marketing name for the worldwide operations of American International Group, Inc. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408242557/en/


Permalink
https://www.aetoswire.com/en/news/9042024386099
Contacts
Corebridge Contacts:
Işıl Müderrisoğlu (Investors): investorrelations@corebridgefinancial.com
Matt Ward (Media): media.contact@corebridgefinancial.com

AIG Contacts:
Quentin McMillan (Investors): quentin.mcmillan@aig.com
Claire Talcott (Media): claire.talcott@aig.com

View older posts »

Search

Comments

There are currently no blog comments.